Strangles (intranasal or IM)

Strangles vaccine is designed to protect horses against infection with Streptococcus equi subspecies equi, the bacterial pathogen responsible for causing strangles, one of the most common and highly contagious infectious diseases of horses worldwide. This risk-based vaccine is available in two distinct formulations: a modified live intranasal vaccine and an inactivated injectable product administered intramuscularly. Each formulation has specific advantages, considerations, and protocols that must be understood for appropriate use in equine populations at risk for this economically significant disease.

Strangles, sometimes called equine distemper, causes distinctive clinical signs including high fever, thick nasal discharge, and painful swelling and abscessation of the lymph nodes of the head and throat, particularly those beneath the jaw and in the throatlatch area. The disease derives its common name from severe cases where enlarged lymph nodes can compress the airway and cause difficulty breathing. While strangles is rarely fatal in otherwise healthy adult horses with proper care, it causes significant morbidity, extended recovery periods, and can spread explosively through susceptible populations, making prevention highly valuable.

The intranasal modified live vaccine stimulates local immunity at the site where natural infection begins, potentially providing protection at the mucosal surfaces of the upper respiratory tract. This approach mimics aspects of natural infection without causing full clinical disease in most horses. The intramuscular inactivated vaccine stimulates systemic antibody responses through killed bacterial antigens and adjuvants. Each vaccine type has different efficacy profiles, side effect concerns, and appropriate use scenarios that veterinarians consider when recommending strangles vaccination for specific horses or populations.

The safety profile of strangles vaccines requires careful consideration, as both formulations can cause adverse reactions in some horses. The modified live intranasal vaccine can occasionally cause clinical disease-like signs including abscess formation at injection sites if accidentally administered intramuscularly. The inactivated vaccine has been associated with purpura hemorrhagica in horses with high pre-existing antibody levels from recent natural infection. Veterinary oversight is essential for proper patient selection, appropriate product choice, and monitoring for adverse events.

The primary indication for strangles vaccination is prevention of Streptococcus equi infection in horses at elevated risk of exposure to the pathogen. Risk factors include housing at facilities with transient horse populations, frequent travel to competitions or events, contact with horses from multiple sources, and residence at farms with documented strangles history. Vaccination aims to reduce the likelihood of infection, decrease disease severity if infection occurs, and limit outbreak spread within horse populations.

Boarding facilities and training barns with horses coming and going from various sources represent high-risk environments where strangles vaccination is commonly recommended. The regular introduction of new horses creates ongoing opportunities for pathogen introduction, even when individual horses appear healthy. Subclinical carriers can shed Streptococcus equi for extended periods, potentially introducing infection to naive populations. Maintaining vaccination in resident horse populations provides a baseline of protection against these ongoing exposure risks.

Show horses, event horses, and others that travel frequently to competitions face repeated exposure opportunities at venues where horses from diverse backgrounds congregate. Even brief contact at trailer parking areas, wash racks, or warm-up arenas can transmit strangles between susceptible animals. Horses with active competition schedules may benefit from regular strangles vaccination as part of comprehensive biosecurity programs that also include careful attention to hygiene and limiting direct contact with unknown horses.

Young horses entering training programs or being introduced to group housing situations often encounter Streptococcus equi for the first time after losing maternal antibody protection. These immunologically naive animals are particularly susceptible to infection and may develop more severe disease than previously exposed adults. Vaccinating young horses before introduction to high-risk environments can help establish immunity before natural exposure occurs.

Farms with documented strangles outbreaks or endemic infection may use vaccination as part of disease control efforts, though the role of vaccination during active outbreaks is complex and requires veterinary guidance. Vaccination of uninfected horses during outbreaks may help limit spread by establishing immunity in susceptible individuals before they are exposed. However, recently infected or exposed horses should generally not be vaccinated due to concerns about adverse reactions in horses with elevated antibody levels from recent natural infection.

The administration of strangles vaccine varies significantly depending on the formulation chosen, and proper technique is essential for safety and efficacy. All strangles vaccinations should be performed by or under the direct supervision of a licensed veterinarian who can ensure appropriate product selection, proper administration technique, and adequate patient monitoring. The choice between intranasal and intramuscular products depends on individual patient factors, farm circumstances, and veterinary judgment.

The intranasal modified live vaccine is administered by directing the liquid vaccine into the horse's nostril using the applicator provided with the product. The horse's head should be elevated during and briefly after administration to help retain the vaccine in the nasal passages. Both nostrils are typically treated as part of the complete dose. This administration method requires patient cooperation and proper restraint, as head movement during administration can result in incomplete dosing or accidental ocular exposure, which should be avoided.

The primary series for intranasal vaccination typically consists of two doses administered two to three weeks apart. Some protocols may recommend an additional dose, particularly for horses at very high risk or those with unknown vaccination history. Annual revaccination is generally recommended for horses with ongoing exposure risk, though more frequent boosters may be appropriate for horses facing continuous high-risk situations. The veterinarian will establish an appropriate schedule based on individual circumstances.

The intramuscular inactivated vaccine is administered via injection into the large muscles of the neck or hindquarters using standard injection technique. Proper aseptic handling and accurate injection depth are important to minimize local reactions. The injection site should be clean and the veterinarian will use appropriate needle selection based on the horse's body condition. Documentation of injection location helps with monitoring for any local reactions.

Pre-vaccination screening is an important consideration with strangles vaccines due to the association between vaccination and adverse reactions in horses with high antibody levels from recent infection. Serological testing can identify horses with elevated antibodies who should not be vaccinated. Some veterinarians recommend screening all horses before strangles vaccination, while others may focus on horses with unknown histories or those from farms with recent disease activity. The cost and practicality of screening must be weighed against the risk of adverse reactions.

Critical safety note: The intranasal modified live vaccine must never be administered by injection. Accidental intramuscular administration of this product can cause severe local abscesses at the injection site and potentially serious systemic illness. Product labeling, storage, and handling should clearly distinguish intranasal products from injectable vaccines to prevent this dangerous error. Any suspicion of accidental injection of intranasal vaccine requires immediate veterinary attention.

Strangles vaccines can cause a range of adverse reactions that vary between the intranasal and intramuscular formulations. Understanding the specific side effect profiles of each vaccine type helps guide product selection and enables appropriate monitoring following vaccination. The potential for significant adverse reactions makes careful patient selection and veterinary oversight particularly important for strangles vaccination compared to many other equine vaccines.

The intranasal modified live vaccine commonly causes mild nasal discharge and slight fever in the days following administration, representing normal mucosal immune responses to the vaccine organisms. Some horses may appear mildly depressed or show decreased appetite for one to two days. More concerning reactions include development of actual strangles-like disease with lymph node swelling and abscess formation, which can occur in a small percentage of vaccinated horses. These reactions are more likely in horses with compromised immune function or those that have recently been exposed to natural infection.

If intranasal vaccine is accidentally administered by injection, severe local reactions occur at the injection site including abscess formation, extensive swelling, and tissue necrosis. These injection site abscesses require aggressive treatment and can result in permanent scarring or loss of muscle tissue. Systemic illness may also develop following accidental injection. This iatrogenic complication, while entirely preventable with proper vaccine handling, represents one of the most serious potential adverse events in equine vaccination.

The intramuscular inactivated vaccine causes local injection site reactions including swelling, pain, and firmness that may be more pronounced than with many other injectable vaccines. These local reactions can be extensive in some horses and may persist for days to weeks. Systemic reactions including fever and malaise can also occur. The most serious concern with intramuscular strangles vaccine is the potential to trigger purpura hemorrhagica, an immune-mediated condition causing small vessel damage, tissue swelling, and bleeding.

Purpura hemorrhagica associated with strangles vaccination represents a serious adverse event requiring immediate veterinary treatment. This condition typically occurs in horses with high pre-existing antibody levels from recent natural strangles infection who receive additional antigenic stimulation from vaccination. Signs include widespread limb edema, petechial hemorrhages on mucous membranes, skin lesions with serum oozing, and severe systemic illness. The risk of purpura hemorrhagica underscores the importance of screening horses for recent infection before strangles vaccination.

Horses with recent Streptococcus equi infection or exposure should not receive strangles vaccination due to the risk of triggering purpura hemorrhagica. High circulating antibody levels from recent natural infection can lead to immune complex formation when additional antigens are introduced through vaccination, causing vasculitis and the potentially life-threatening purpura hemorrhagica syndrome. Horses should generally not be vaccinated within several months of documented strangles infection, and serological screening before vaccination can identify horses with elevated antibody levels requiring postponement of vaccination.

Horses with documented hypersensitivity to strangles vaccine components should not receive the same product again. This includes horses that have experienced anaphylactic reactions, severe injection site abscesses beyond those caused by accidental injection of intranasal product, or purpura hemorrhagica following previous vaccination. Alternative prevention strategies including strict biosecurity may be necessary for horses that cannot safely receive available strangles vaccines.

Immunocompromised horses present particular concerns with modified live intranasal strangles vaccine. Horses with impaired immune function from disease, medication, or stress may be unable to control the vaccine strain organisms, potentially developing actual clinical disease following vaccination. The decision to use live intranasal vaccine in immunocompromised horses should be made carefully, weighing the risk of vaccine-induced disease against the risk of natural infection. Inactivated vaccines may be preferred in these patients, though they also have limitations.

Pregnant mares should not receive the modified live intranasal strangles vaccine due to the theoretical risk of fetal infection or pregnancy complications from the live bacterial organisms. The inactivated injectable vaccine may be considered for pregnant mares at high risk, but the decision should be made carefully with veterinary guidance weighing risk and benefit. Many practitioners prefer to ensure mares are appropriately vaccinated before breeding rather than during pregnancy.

Interactions between strangles vaccine and other medications or vaccines require careful consideration, particularly given the potential for significant adverse reactions with this vaccine. General principles of vaccine immunology and antimicrobial pharmacology guide recommendations, though specific interaction studies are limited. Thorough communication with the veterinarian about all current medications and recent treatments is essential for safe strangles vaccination.

Antimicrobial medications active against Streptococcus equi can interfere with the modified live intranasal vaccine. Since this vaccine depends on limited replication of the attenuated bacterial strain to stimulate immunity, concurrent antibiotic therapy can kill the vaccine organisms before adequate immune stimulation occurs. Horses should ideally complete any antibiotic treatment several days before intranasal vaccination. The inactivated vaccine is not affected by antibiotics since it contains killed organisms.

Corticosteroids and other immunosuppressive medications affect the immune response to both vaccine formulations. Immunosuppression may prevent adequate antibody and cell-mediated immune responses to the inactivated vaccine, while potentially allowing excessive replication of the live intranasal vaccine strain. When possible, strangles vaccination should be timed to avoid periods of immunosuppressive therapy. For horses requiring ongoing immunosuppression, careful risk-benefit analysis guides vaccination decisions.

Concurrent administration of multiple vaccines may affect immune responses and complicates monitoring for adverse reactions. Given the potential for significant local and systemic reactions with strangles vaccines, many practitioners prefer to administer this vaccine separately from other immunizations with at least two to four weeks between different products. If multiple vaccines must be given in a single visit, using different injection sites and clear documentation facilitates monitoring and troubleshooting of any adverse events.

Pre-vaccination serological screening is strongly recommended to identify horses with elevated Streptococcus equi antibody levels who face increased risk of adverse reactions, particularly purpura hemorrhagica. Several testing options exist for measuring antibody levels, and veterinarians can advise on appropriate testing for individual circumstances. Horses with positive or elevated titers should have vaccination postponed until antibody levels decline, typically requiring several months to a year or more depending on the degree of elevation.

The distinction between intranasal and intramuscular strangles vaccine products cannot be overemphasized. Accidental intramuscular administration of intranasal product causes severe local reactions and potentially serious systemic illness. Product labeling, storage location, and handling protocols should ensure clear differentiation between vaccine types. Personnel administering vaccines should be trained to verify product identity before every administration. Any suspected accidental injection of intranasal product requires immediate veterinary notification.

Post-vaccination monitoring should continue for extended periods given the potential for delayed adverse reactions. While immediate allergic reactions occur within hours, vaccine-associated abscesses or disease signs may not develop for days to weeks following vaccination. Purpura hemorrhagica can appear one to four weeks after vaccination in susceptible individuals. Owners should be instructed on signs to watch for and when to contact the veterinarian.

Vaccination does not guarantee protection, and strangles can still occur in vaccinated horses, particularly if exposure is intense or involves strains with antigenic differences from vaccine strains. Vaccinated horses may develop milder disease than unvaccinated animals, but should not be considered immune. Biosecurity measures including quarantine of new arrivals, isolation of sick horses, and basic hygiene remain important components of strangles prevention alongside vaccination.

Horses that have recovered from natural strangles infection typically develop solid immunity that may last for years, reducing or eliminating the need for vaccination. The optimal approach for previously infected horses depends on the time since infection, documented antibody levels, and ongoing risk factors. Some previously infected horses may not need vaccination at all, while others may benefit from carefully timed vaccination after antibody levels have declined sufficiently to make vaccination safe.

Proper storage of strangles vaccines is essential for maintaining product potency and ensuring safe, effective vaccination. The intranasal and intramuscular formulations have similar storage requirements but must be clearly differentiated to prevent the dangerous error of injecting intranasal product. Cold chain maintenance from manufacturer through administration protects vaccine components necessary for appropriate immune stimulation.

Both vaccine formulations must be stored at refrigerator temperature between 35 and 45 degrees Fahrenheit, protected from light and freezing. Freezing destroys vaccine organisms and antigens, rendering products ineffective. Temperature fluctuations during storage can progressively compromise vaccine potency. Dedicated refrigerators with temperature monitoring capabilities should be used, and vaccines should not be stored in door compartments where temperatures vary most significantly.

The intranasal modified live vaccine requires reconstitution before administration using the diluent provided. Reconstituted vaccine must be used promptly, typically within one to two hours, as the viability of the modified live organisms declines rapidly once the product is mixed. Any unused reconstituted vaccine should be disposed of properly rather than refrigerated for later use. The injectable inactivated vaccine may be ready to use or may require mixing depending on the specific product formulation.

Strangles can affect horses of any breed, with susceptibility determined by immune status and exposure rather than genetic factors. Young horses of all breeds are generally more susceptible than adults with previous exposure. Vaccination recommendations are based on risk factors and management rather than breed-specific considerations. The standard vaccine protocols apply across breeds, as immune response to vaccination does not differ substantially between horse types.

Thoroughbreds and other racing breeds frequently move between training facilities, racetracks, and sales venues, creating multiple exposure opportunities for strangles. The economic impact of disease outbreaks in racing populations, combined with the intensive management systems used, makes strangles prevention a significant concern. Vaccination programs must be coordinated with training and racing schedules to avoid performance impacts from post-vaccination reactions.

Warmblood sport horses similarly face elevated exposure risk through frequent competition travel and housing at busy training facilities. The extended competition seasons for many sport horse disciplines mean ongoing exposure risk that may warrant regular booster vaccination. The potential for injection site reactions is a consideration when selecting vaccine formulation, as visible swelling or scarring could affect competition presentation in disciplines where appearance is evaluated.

Ponies and miniature horses do not require dose adjustments for strangles vaccination, as immune stimulation is the goal rather than therapeutic drug levels proportional to body weight. These smaller equines may be at risk in educational programs, petting zoos, or therapeutic riding settings where they contact many different people and potentially other equines. Their inclusion in comprehensive vaccination programs depends on individual risk assessment.

Draft breeds may experience more pronounced injection site reactions to intramuscular vaccines due to their larger muscle masses and tissue characteristics, though this is not consistently documented. The standard vaccine volume applies regardless of horse size. Draft horses at breeding farms, shows, or pulling competitions face exposure risks warranting vaccination consideration based on their specific management and activities.

Strangles vaccine is one of several vaccines targeting respiratory and pharyngeal pathogens in horses. Other vaccines addressing upper respiratory disease include those for equine influenza and equine herpesvirus types 1 and 4, which cause respiratory illness distinct from bacterial strangles. A comprehensive respiratory disease prevention program for horses at high exposure risk may include vaccination against multiple pathogens based on individual circumstances and veterinary recommendations.

Core vaccines recommended for all horses regardless of specific risk factors include those for tetanus, Eastern and Western equine encephalomyelitis, West Nile virus, and rabies. These vaccines protect against diseases with severe consequences or public health implications. Strangles vaccine is administered in addition to rather than instead of these essential core immunizations. The vaccination schedule should coordinate strangles vaccine with other products while maintaining appropriate spacing between different antigens.

Treatment of clinical strangles relies primarily on supportive care and, in appropriate cases, antimicrobial therapy with penicillin or other antibiotics active against Streptococcus equi. Treatment decisions including whether and when to use antibiotics should be made by the attending veterinarian based on disease stage and individual patient factors. Non-steroidal anti-inflammatory medications may provide symptomatic relief for fever and pain. Horses developing purpura hemorrhagica following vaccination or natural infection require intensive treatment including corticosteroids and supportive care. No therapeutic vaccine or antitoxin exists for treating established strangles infection, emphasizing the value of prevention.